Prudential Financial Inc. Has $17.41 Million Position in IQVIA Holdings Inc. $IQV

Prudential Financial Inc. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 9.5% in the second quarter, HoldingsChannel reports. The firm owned 110,498 shares of the medical research company’s stock after buying an additional 9,543 shares during the period. Prudential Financial Inc.’s holdings in IQVIA were worth $17,413,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. Trust Co. of Toledo NA OH acquired a new stake in IQVIA in the second quarter valued at approximately $39,000. J.Safra Asset Management Corp increased its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 169 shares in the last quarter. Rothschild Investment LLC raised its position in shares of IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the period. Finally, NewSquare Capital LLC grew its position in IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 189 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of IQVIA stock opened at $231.56 on Thursday. The business’s fifty day simple moving average is $208.43 and its 200 day simple moving average is $182.71. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The firm has a market capitalization of $39.43 billion, a P/E ratio of 31.76, a price-to-earnings-growth ratio of 2.60 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IQV. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research note on Wednesday, September 3rd. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. UBS Group boosted their price objective on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, BMO Capital Markets initiated coverage on IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $240.61.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.